• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Shuttle Pharmaceuticals Holdings Inc.

    5/12/26 4:15:06 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SHPH alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

     

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
     
    Check the appropriate box:
     
    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material under §240.14a-12

     

    SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
    (Name of Registrant as Specified In Its Charter)
     
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):
     
    ☒ No fee required.
       
    ☐ Fee paid previously with preliminary material.
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     
     

     

    SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

    401 Professional Drive, Suite 260

    Gaithersburg, Maryland 20879

     

    SUPPLEMENT TO

    NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

    AND PROXY STATEMENT DATED APRIL 20, 2026

    FOR ANNUAL MEETING OF STOCKHOLDERS

    TO BE HELD ON MAY 21, 2026

     

    This Supplement provides updated information with respect to the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation, to be held on Thursday, May 21, 2026 at 12:00 p.m. Eastern Time. Unless the context otherwise requires, references to the “Company,” “we,” and “our” refer to Shuttle Pharmaceuticals Holdings, Inc.

     

    The Company previously distributed its Notice of Annual Meeting of Stockholders and Proxy Statement (the “Notice and Proxy Statement”) for the Annual Meeting. This Supplement, which describes a recent change in the proposed nominees for election to the Company’s Board of Directors (the “Board”), should be read in conjunction with the Notice and Proxy Statement.

     

    Withdrawal of Nominee for Election as Director

     

    As previously disclosed by the Company on a Current Report on Form 8-K filed with the Securities and Exchange Commission on May 7, 2026, Oleh Nabyt, previously a director of the Company, notified the Company of his decision to resign from the Board, effective immediately. Mr. Nabyt’s decision to resign from the Board was not related to a disagreement with the Company over any of its operations, policies or practices. Accordingly, the nomination of Mr. Nabyt for re-election to the Board at the Annual Meeting has been withdrawn.

     

    In light of Mr. Nabyt’s resignation from the Board and the subsequent withdrawal of his name as a nominee for re-election to the Board, Proposal No. 1 in the Notice and Proxy Statement now proposes to elect the remaining four director nominees named in the Proxy Statement to hold office until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified.

     

    THE BOARD RECOMMENDS A VOTE FOR THE ELECTION OF EACH OF THE REMAINING FOUR DIRECTOR NOMINEES

     

    Voting Matters

     

    If you have already voted, you do not need to take any action unless you wish to change your vote. Proxy voting cards already returned by stockholders will remain valid and will be voted at the Annual Meeting unless revoked.

     

    If we receive a proxy instruction from you before the Annual Meeting, your shares will be voted for the directors nominated by the Board as instructed by you, except that votes will not be cast for Oleh Nabyt because he has resigned from the Board and is no longer standing for re-election. If you have not yet voted, please complete the Proxy Card or submit your voting instructions, disregarding Mr. Nabyt’s name as a nominee for election as director.

     

    None of the other agenda items presented in the Notice and Proxy Statement are affected by this Supplement, and shares represented by proxy instructions returned before the Annual Meeting will be voted with respect to all other matters properly brought before the Annual Meeting in accordance with those voting instructions.

     

    Information regarding how to vote your shares, or revoke your proxy or voting instructions, is available in the Proxy Statement.

     

      By order of the Board of Directors,
       
      Christopher Cooper
      Interim Chief Executive Officer

     

     

     

    Get the next $SHPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SHPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SHPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs

    Initial Mining Fleet Targeted for Deployment Within 60 Days of Receipt; To Mine DOGE and LTC and Accumulate Mined Coins as Long-Term Treasury AssetsGaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced the closing (the "Closing") of its previously announced merger with United Dogecoin Inc. ("United Dogecoin"), and the confirmation of a purchase order granting the Company the option to purchase up to 3,000 next-generation ElphaPex Scrypt mining rigs ("Mining Rigs") for use in the Company's Dogecoin (DOGE) and Litecoin (LTC) merge-mining operations. As previously reported on Shuttle's Current R

    5/14/26 4:05:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner

    NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced it served as exclusive M&A advisor and placement agent in connection with the successful closing of Shuttle Pharmaceuticals Holdings, Inc.'s (NASDAQ:SHPH) acquisition of United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. The transaction, completed pursuant to a definitive merger agreement, resulted in United Dogecoin merging into a wholly owned subsidiary of Shuttle Pharmaceuticals, creating one of the largest publicly traded Dogecoin mining platforms. In connection with the mer

    5/7/26 2:02:34 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner

    The combination and related financing is expected to result in the largest publicly listed Dogecoin mining company based on percentage of the global hashrateGaithersburg, Maryland--(Newsfile Corp. - April 30, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. United Dogecoin will be merged into a wholly owned subsidiary of Shuttle. The merger is supported by a $11 million concurrent Private Investment in Public Equity ("PIPE") financing expected to close on May 4, 2026. United Dogecoin's competitive adv

    4/30/26 4:05:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    SEC Filings

    View All

    Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    5/27/26 9:00:14 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Shuttle Pharmaceuticals Holdings Inc.

    D - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    5/15/26 4:45:23 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.

    10-Q - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    5/15/26 4:31:42 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Trasolini Ryan

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    6/1/26 7:11:22 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Liang Yuying

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    1/12/26 4:15:20 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Liriano Angel claimed no ownership of stock in the company (SEC Form 3)

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    10/29/25 2:05:48 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Shuttle Pharmaceuticals Holdings Inc. (Amendment)

    SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

    10/17/23 6:57:47 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Shuttle Pharmaceuticals Holdings Inc.

    SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

    5/30/23 5:30:57 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Leadership Updates

    Live Leadership Updates

    View All

    Shuttle Pharmaceuticals Acquires AI Health Platform

    Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay

    11/21/25 9:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

    GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Heal

    6/4/25 4:01:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

    GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities. "I am excited to welcome Christopher Cooper as Co-CEO of

    3/12/25 6:20:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care